

Wyeth Holdings LLC
100 Route 206 North
Peapack, NJ 07977

Susan Grant
Vice President & Secretary

Wyeth

December 18, 2014

To
The Manager,
Compliance Department
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
MUMBAI - 400 001.
FAX NO. : 022 2272 3121

The Manager,
Compliance Department
National Stock Exchange of India Ltd.
Exchange Plaza, 5th floor,
Plot No. - C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051.
FAX NO. : 022 26598237/38

Mr. Prajeet Nair
Company Secretary
Pfizer Limited
Patel Estate, Off S.V. Road,
Jogeshwari (W),
Mumbai - 400 102
India

Dear Sirs:


Sub: Submission under Regulation 10(6) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations 2011

Enclosed please find the disclosure under Regulation 10(6) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations 2011 in the prescribed format.

Kindly take the same on record.

Thank you,

Yours very truly,
For Wyeth Holdings LLC, USA
(Formerly known as Wyeth Holdings Corporation, USA)



Susan Grant, Vice President & Secretary

Encls. a/a

Format for Disclosures under Regulation 10(6) – Report to Stock Exchanges in respect of any acquisition made in reliance upon exemption provided for in Regulation 10 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1.	Name of the Target Company (TC)	Pfizer Limited	
2.	Name of the acquirer(s)	Wyeth Holdings LLC, USA (Formerly known as Wyeth Holdings Corporation, USA)	
3.	Name of the stock exchange where shares of the TC are listed	• BSE Limited • National Stock Exchange of India Limited	
4.	Details of the transaction including rationale, if any, for the transfer/ acquisition of shares.	The allotment of new equity shares has been made pursuant to the Scheme of Amalgamation of Wyeth Limited with Pfizer Limited and their respective shareholders and creditors under sections 391-394 of the Companies Act, 1956 which was sanctioned on October 31, 2014, by the Hon'ble Bombay High Court and as per the following share exchange ratio provided in the Scheme of Amalgamation: 7 fully paid up equity shares of Rs. 10 each of Pfizer Limited for every 10 fully paid up equity shares of Rs. 10 each of Wyeth Limited.	
5.	Relevant regulation under which the acquirer is exempted from making open offer.	Regulation 10(1)(d)(ii) – Acquisition pursuant to the Scheme of Amalgamation which was approved on October 31, 2014, by the Hon'ble Bombay High Court whereby the Target Company is the Transferee Company.	
6.	Whether disclosure of proposed acquisition was required to be made under regulation 10 (5) and if so, - whether disclosure was made and whether it was made within the timeline specified under the regulations. - date of filing with the stock exchange.	Not Applicable	
7.	Details of acquisition	Disclosures required to be made under regulation 10(5)	Whether the disclosures under regulation 10(5) are actually made
	a. Name of the transferor / seller	Not Applicable	Not Applicable
	b. Date of acquisition	Not Applicable	Not Applicable
	c. Number of shares/ voting rights in respect of the acquisitions from each person mentioned in 7(a) above	Not Applicable	Not Applicable
	d. Total shares proposed to be acquired / actually acquired as a % of diluted share capital of TC	Not Applicable	Not Applicable

	e.	Price at which shares are proposed to be acquired / actually acquired	Not Applicable		Not Applicable	
8.	Shareholding details		Pre-Transaction		Post transaction	
			No. of shares held	% w.r.t total share capital of TC	No. of shares held	% w.r.t total share capital of TC
	a	Each Acquirer / Transferee – Wyeth Holdings LLC, USA (Formerly known as Wyeth Holdings Corporation, USA)	Nil	Nil	1630164	3.56
	b	Each Seller / Transferor	Not Applicable	Not Applicable	Not Applicable	Not Applicable

FOR Wyeth Holdings LLC, USA
(Formerly known as Wyeth Holdings Corporation, USA)



Susan Grant, Vice President & Secretary

Place : Peapack, NJ U.S.A.

Date : December 18, 2014